Health care stocks advanced Thursday afternoon, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%.
The iShares Biotechnology ETF (IBB) shed 0.5%.
In corporate news, UnitedHealth Group's (UNH) Q4 results increased on an annual basis, but revenue fell short of market expectations, while the health insurer kept its full-year outlook unchanged on Thursday. Its shares dropped 5.4%.
Biomerica (BMRA) shares surged 85% after the company said Thursday its Fortel prostate-specific antigen screening test has been approved by the United Arab Emirates Ministry of Health and Prevention for detection of prostate cancer.
Atara Biotherapeutics (ATRA) shares fell 38% after the company reported "compliance issues" involving a third-party manufacturing facility for Ebvallo, a treatment for people with Epstein-Barr virus positive post-transplant lymphoproliferative disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。